Trial Profile
Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Mar 2023 Planned End Date changed from 31 Jul 2023 to 30 Jun 2025.
- 18 Mar 2023 Planned primary completion date changed from 31 Jul 2023 to 30 Jun 2025.
- 10 Dec 2022 Status changed from suspended to recruiting.